Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.3
Journals
Nanomaterials
Special Issues
Application of Lipid Nanoparticles in Drug and Gene Delivery
share announcement

Application of Lipid Nanoparticles in Drug and Gene Delivery

A special issue of Nanomaterials (ISSN 2079-4991). This special issue belongs to the section "Biology and Medicines".

Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 3191

Special Issue Editor

Dr. Tatiana Pashirova

E-Mail Website
Guest Editor
Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, 420088 Kazan, Russia
Interests: supramolecular chemistry; delivery systems; solid lipid nanoparticles; liposomes; nanoreactors; colloidal systems; surfactants; micellar catalysis

Special Issue Information

Dear Colleagues,

Among the existing variety of nanoparticles, lipid nanoparticles, liposomes, solid lipid nanoparticles, nano-emulsions, and nanocrystals have advantages over other types of nanoparticles for drug delivery. 

Lipid systems are natural and biodegradable materials with low toxicity and biocompatibility, thus meeting preclinical safety requirements. An urgent problem for the treatment of diseases is both the effectiveness of drugs and the complexity of their delivery to pathological targets. Overcoming the biological barriers, such as the blood–brain barrier; the skin or mucous membranes of the small intestine, nose, mouth, and eyes, is often a challenge. Another difficulty encountered is the immune responses that the body uses to get rid of nanomaterials. Thus, the most efficient delivery system helps to protect the drug from the immune response and allows the drug to cross biological barriers.

The purpose of this Special Issue is lipid nanoforms of a new generation, namely, ligand-targeted, sensitive to stimuli, capable of improving the physicochemical and biological properties and achieving the maximum therapeutic effect. This Special Issue welcomes original research papers and comprehensive reviews that demonstrate or summarize significant advances about biomedical applications of lipid nanoparticles for the treatment of socially significant diseases. Original works aimed at creating new lipid materials, including synthesis of new lipid compounds, new lipid compositions, new generation of lipid carriers with improved properties and applications in nanomedicine, are welcome.

Dr. Tatiana Pashirova
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nanomaterials is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lipids
  • phospholipids
  • surfactants
  • amphiphilic compounds
  • self-assembly
  • supramolecular chemistry
  • drug delivery
  • vesicles
  • liposomes
  • solid lipid nanoparticles
  • nanoemulsions

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

36 pages, 5840 KiB  
Article
Novel Mitochondria-Targeted Amphiphilic Aminophosphonium Salts and Lipids Nanoparticles: Synthesis, Antitumor Activity and Toxicity
by Vladimir F. Mironov, Mudaris N. Dimukhametov, Andrey V. Nemtarev, Tatiana N. Pashirova, Olga V. Tsepaeva, Alexandra D. Voloshina, Alexandra B. Vyshtakalyuk, Igor A. Litvinov, Anna P. Lyubina, Anastasiia S. Sapunova, Dinara F. Abramova and Vladimir V. Zobov
Nanomaterials 2023, 13(21), 2840; https://doi.org/10.3390/nano13212840 - 26 Oct 2023
Viewed by 1134
Abstract
The creation of mitochondria-targeted vector systems is a new tool for the treatment of socially significant diseases. Phosphonium groups provide targeted delivery of drugs through biological barriers to organelles. For this purpose, a new class of alkyl(diethylAmino)(Phenyl) Phosphonium halides (APPs) containing one, two, [...] Read more.
The creation of mitochondria-targeted vector systems is a new tool for the treatment of socially significant diseases. Phosphonium groups provide targeted delivery of drugs through biological barriers to organelles. For this purpose, a new class of alkyl(diethylAmino)(Phenyl) Phosphonium halides (APPs) containing one, two, or three diethylamino groups was obtained by the reaction of alkyl iodides (bromides) with (diethylamino)(phenyl)phosphines under mild conditions (20 °C) and high yields (93–98%). The structure of APP was established by NMR and XRD. A high in vitro cytotoxicity of APPs against M-HeLa, HuTu 80, PC3, DU-145, PANC-1, and MCF-7 lines was found. The selectivity index is in the range of 0.06–4.0 μM (SI 17-277) for the most active APPs. The effect of APPs on cancer cells is characterized by hyperproduction of ROS and depolarization of the mitochondrial membrane. APPs induce apoptosis, proceeding along the mitochondrial pathway. Incorporation of APPs into lipid systems (liposomes and solid lipid nanoparticles) improves cytotoxicity toward tumor cells and decrease toxicity against normal cell lines. The IC50s of lipid systems are lower than for the reference drug DOX, with a high SI (30–56) toward MCF-7 and DU-145. APPs exhibit high selective activity against Gram-positive bacteria S. aureus 209P and B. segeus 8035, including methicillin-resistant S. aureus (MRSA-1, MRSA-2), comparable to the activity of the fluoroquinolone antibiotic norfloxacin. A moderate in vivo toxicity in CD-1 mice was established for the lead APP. Full article
(This article belongs to the Special Issue Application of Lipid Nanoparticles in Drug and Gene Delivery)
►▼ Show Figures

Figure 1

28 pages, 5349 KiB  
Article
Liposome Formulations for the Strategic Delivery of PARP1 Inhibitors: Development and Optimization
by Carlota J. F. Conceição, Elin Moe, Paulo A. Ribeiro and Maria Raposo
Nanomaterials 2023, 13(10), 1613; https://doi.org/10.3390/nano13101613 - 11 May 2023
Cited by 1 | Viewed by 1628
Abstract
The development of a lipid nano-delivery system was attempted for three specific poly (ADP-ribose) polymerase 1 (PARP1) inhibitors: Veliparib, Rucaparib, and Niraparib. Simple lipid and dual lipid formulations with 1,2-dipalmitoyl-sn-glycero-3-phospho-rac-(1′-glycerol) sodium salt (DPPG) and 1,2-dipalmitoyl-sn-glycero-3-phosphocoline (DPPC) were developed and tested following the thin-film [...] Read more.
The development of a lipid nano-delivery system was attempted for three specific poly (ADP-ribose) polymerase 1 (PARP1) inhibitors: Veliparib, Rucaparib, and Niraparib. Simple lipid and dual lipid formulations with 1,2-dipalmitoyl-sn-glycero-3-phospho-rac-(1′-glycerol) sodium salt (DPPG) and 1,2-dipalmitoyl-sn-glycero-3-phosphocoline (DPPC) were developed and tested following the thin-film method. DPPG-encapsulating inhibitors presented the best fit in terms of encapsulation efficiency (>40%, translates into concentrations as high as 100 µM), zeta potential values (below −30 mV), and population distribution (single population profile). The particle size of the main population of interest was ~130 nm in diameter. Kinetic release studies showed that DPPG-encapsulating PARP1 inhibitors present slower drug release rates than liposome control samples, and complex drug release mechanisms were identified. DPPG + Veliparib/Niraparib presented a combination of diffusion-controlled and non-Fickian diffusion, while anomalous and super case II transport was verified for DPPG + Rucaparib. Spectroscopic analysis revealed that PARP1 inhibitors interact with the DPPG lipid membrane, promoting membrane water displacement from hydration centers. A preferential membrane interaction with lipid carbonyl groups was observed through hydrogen bonding, where the inhibitors’ protonated amine groups may be the major players in the PARP1 inhibitor encapsulation mode. Full article
(This article belongs to the Special Issue Application of Lipid Nanoparticles in Drug and Gene Delivery)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop